VICTORIA, BC, June 8, 2022
/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the
"Company") (TSX: EPRX) a clinical-stage biotechnology company with
an innovative drug delivery platform technology, announced today
that its CEO, Dr. James Helliwell,
will present at the 2022 Bio International Convention being held at
the San Diego Convention Center
from June 13-16, 2022, in
San Diego, CA.
The BIO International Convention returns in person for the first
time in three years and brings together key international industry
stakeholders for networking and partnering. It also hosts more than
100 informative sessions that cover relevant and timely topics such
as narrowing the health equity gap, vaccine innovation, and
preparing for the next pandemic.
About BIO
BIO is the world's largest advocacy organization representing
biotechnology companies, academic institutions, state biotechnology
centers and related organizations across the United States and in more than 30 other
nations. BIO members are involved in the research and development
of innovative healthcare, agricultural, industrial and
environmental biotechnology products. BIO also produces the BIO
International Convention, the world's largest gathering of the
biotechnology industry, along with industry-leading investor and
partnering meetings held around the world.
About Eupraxia Pharmaceutical
Inc.
Eupraxia is a clinical-stage biotechnology company focused on
the development of locally delivered, extended-release alternatives
to currently approved drugs. Each of Eupraxia's product candidates
has the potential to address therapeutic areas with high unmet
medical need and strives to provide improved patient benefit by
delivering targeted, long-lasting activity with fewer side
effects.
Eupraxia's lead product candidate, EP-104IAR, is currently in
Phase 2 development for the treatment of pain due to OA of the
knee. In addition to EP-104IAR, Eupraxia is developing a pipeline
of earlier-stage long-acting formulations. Potential pipeline
candidates include a range of drugs for indications such as
postsurgical pain (EP-105), and post-surgical site infections
(EP-201), each designed to improve on the activity and tolerability
of approved drugs. For further details about Eupraxia, please visit
the Company's website at: www.eupraxiapharma.com.
SOURCE Eupraxia Pharmaceuticals Inc.